文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET/MRI与单独MRI用于疑似复发性盆腔癌女性全身分期及对治疗管理潜在影响的比较:一项随访研究

Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-11-21

本研究纳入71例疑似复发性盆腔癌女性,对比18F-FDG PET/MRI与单独MRI的全身分期诊断效能及对治疗管理的潜在影响。PET/MRI正确识别更多复发患者(100% vs 83.6%),对恶性病灶诊断准确率更高(99.2% vs 79.3%),诊断信心更优(2.7±0.5 vs 2.4±0.7)。结论认为PET/MRI诊断表现优异,优于单独MRI,可能改变治疗管理。

要点

  • PET/MRI正确识别复发患者比例高于单独MRI(100% vs 83.6%,p<0.01)。
  • PET/MRI正确识别全部181个恶性病灶(100%),单独MRI仅识别135/181(74.6%)。
  • PET/MRI诊断准确率(99.2% vs 79.3%)及恶性病灶分类诊断信心(2.7±0.5 vs 2.4±0.7)均优于单独MRI。

核心结论

  • PET/MRI在疑似复发性盆腔癌女性全身分期中诊断表现优异,优于单独MRI,基于局部复发和远处转移评估可能改变治疗管理。

研究设计与样本

  • 研究纳入71例连续女性(54±13岁,范围25-80岁),疑似宫颈癌(32例)、卵巢癌(26例)、子宫内膜癌(7例)、外阴癌(4例)和阴道癌(2例)复发,均行PET/MRI(含诊断性增强MRI方案)。
  • PET/MRI与MRI数据集由两名医师分别评估病灶数量、定位、分类(良性/恶性)及诊断信心(3分制,1-3分)。
  • 参考标准基于组织病理学结果和随访影像,诊断准确率及良恶性病灶正确分类比例采用McNemar卡方检验回顾性比较,诊断信心差异采用Wilcoxon检验。

主要发现

  • 55例患者显示癌症复发,PET/MRI正确识别更多复发患者(100% vs 83.6%,p<0.01)。
  • 单独MRI遗漏4/15例盆腔复发患者,并将8/40例远处转移患者错误分类为仅局部复发。
  • 参考标准共检出241个病灶(181个恶性,60个良性);PET/MRI正确识别181/181(100%)恶性病灶,单独MRI正确识别135/181(74.6%),显著低于PET/MRI(p<0.001)。
  • PET/MRI在恶性病灶分类中诊断准确率(99.2% vs 79.3%,p<0.001)和诊断信心(2.7±0.5 vs 2.4±0.7,p<0.001)均优于单独MRI。

临床怎么用

  • 作者认为PET/MRI在疑似复发性盆腔癌女性全身分期中诊断表现优异且优于单独MRI,基于局部复发和远处转移评估可能改变治疗管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the diagnostic performance of 18F-FDG PET/MRI for whole-body staging and potential changes in therapeutic management of women with suspected recurrent pelvic cancer in comparison with MRI alone. METHODS: Seventy-one consecutive women (54 ± 13 years, range: 25-80 years) with suspected recurrence of cervical (32), ovarian (26), endometrial (7), vulvar (4), and vaginal (2) cancer underwent PET/MRI including a diagnostic contrast-enhanced MRI protocol. PET/MRI and MRI datasets were separately evaluated regarding lesion count, localization, categorization (benign/malignant), and diagnostic confidence (3-point scale; 1-3) by two physicians. The reference standard was based on histopathology results and follow-up imaging. Diagnostic accuracy and proportions of malignant and benign lesions rated correctly were retrospectively compared using McNemar's chi2 test. Differences in diagnostic confidence were assessed by Wilcoxon test. RESULTS: Fifty-five patients showed cancer recurrence. PET/MRI correctly identified more patients with cancer recurrence than MRI alone (100% vs. 83.6%, p < 0.01). In contrast to PET/MRI, MRI alone missed 4/15 patients with pelvic recurrence and miscategorized 8/40 patients with distant metastases as having local recurrence only. Based on the reference standard, 241 lesions were detected in the study cohort (181 malignant, 60 benign). While PET/MRI provided correct identification of 181/181 (100%) malignant lesions, MRI alone correctly identified 135/181 (74.6%) malignant lesions, which was significantly less compared to PET/MRI (p < 0.001). PET/MRI offered superior diagnostic accuracy (99.2% vs. 79.3%, p < 0.001) and diagnostic confidence in the categorization of malignant lesions compared with MRI alone (2.7 ± 0.5 vs. 2.4 ± 0.7, p < 0.001). CONCLUSION: PET/MRI demonstrates excellent diagnostic performance and outperforms MRI alone for whole-body staging of women with suspected recurrent pelvic cancer, indicating potential changes in therapy management based on evaluation of local recurrence and distant metastatic spread.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sawicki LM, Kirchner J, Grueneisen J, et al. Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. Eur J Nucl Med Mol Imaging. 2017. PMID: 29164299. doi:10.1007/s00259-017-3881-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。